Abstracts tagged "infection and juvenile idiopathic arthritis (JIA)"

Abstract Number: 2313 • 2017 ACR/ARHP Annual Meeting
Procalcitonin Differentiates Infection from Active Disease in Patients with Juvenile Idiopathic Arthritis
Rebecca Trachtman¹, Elizabeth T. Murray², Nancy Pan³, Sima S Toussi⁴, Marianne E Nellis⁵, Jackie Szymonifka⁶, Sarah Taber³, Alexa Adams³, Thomas J. A. Lehman³, Karen Onel³ and Lisa A. Mandl⁷, ¹Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, NY, NY, ²Hospital for Special Surgery, New York, NY, ³Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ⁴Pediatric Infectious Disease, Weill Cornell Medical College, New York, NY, ⁵Pediatric Critical Care, Weill Cornell Medical College, New York, NY, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY
Background/Purpose: Patients with juvenile idiopathic arthritis (JIA) often present with signs and symptoms suggestive of infection. However, it is a diagnostic challenge to differentiate infectious…
Abstract Number: 402 • 2016 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Associated with Initiation of Abatacept Versus TNF Inhibitors in Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen², Melissa Mannion⁴, Kenneth G. Saag⁵, Jie Zhang⁶ and Jeffrey R. Curtis⁵, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁵Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The comparative risk of infection with newer biologic agents, such as abatacept (ABA), in the treatment of juvenile idiopathic arthritis (JIA) has not been…
Abstract Number: 426 • 2015 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen⁴, Melissa L. Mannion⁵, Kenneth G. Saag⁴, Jie Zhang⁶ and Jeffrey R. Curtis⁴, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic agents are highly effective for the treatment of juvenile idiopathic arthritis (JIA) but have the potential risk of increased serious infections. Using observational…
Abstract Number: 2678 • 2013 ACR/ARHP Annual Meeting
Medically Significant Infections Are Increased In Patients With Juvenile Idiopathic Arthritis Treated With Etanercept. Results From The British Society For Paediatric and Adolescent Rheumatology Etanercept Cohort Study
Rebecca Davies¹, Taunton R. Southwood², Lianne Kearsley-Fleet¹, Mark Lunt³, Kimme L. Hyrich⁴ and on Behalf Of The BSPAR Etanercept Cohort Study⁵, ¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: The association between anti-TNF therapy and increased rate of infection are widely documented in adults with rheumatoid arthritis. Findings in children with juvenile idiopathic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].